You are here

acoramidis

5 FDA decisions to watch in the fourth quarter

BioPharma Dive

Wed, 10/2/24 - 11:24 am

Vertex Pharmaceuticals

PTC Therapeutics

Bristol Myers Squibb

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near

Fierce Biotech

Mon, 09/30/24 - 09:57 am

transthyretin amyloid cardiomyopathy

3 FDA approval dates to watch in the year’s final push

Pharma Voice

Wed, 09/11/24 - 11:39 am

Bristol Myers Squibb

ATTR cardiomyopathy

BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM

BioSpace

Thu, 05/30/24 - 11:30 am

BridgeBio Pharma

clinical trials

Bayer pays $310M to buy into BridgeBio heart drug

BioPharma Dive

Mon, 03/4/24 - 11:52 am

transthyretin amyloidosis cardiomyopathy

AstraZeneca's phase 3 heart disease trial hits, teeing up Pfizer showdown in Japan

Fierce Biotech

Fri, 02/2/24 - 11:53 am

clinical trials

BridgeBio gears up for FDA review of acoramidis following Phase III results

Clinical Trials Arena

Thu, 01/11/24 - 11:07 am

clinical trials

BridgeBio makes $250M in securities sale while planning acoramidis commercial launch

Fierce Biotech

Mon, 09/25/23 - 11:51 am

BridgeBio Pharma

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Yahoo/GlobeNewswire

Sun, 08/27/23 - 04:28 pm

clinical trials

Why BridgeBio Pharma Stock Is Plunging Today

Motley Fool

Thu, 06/15/23 - 06:56 pm

clinical trials

BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal

Seeking Alpha

Mon, 12/27/21 - 11:16 am

clinical trials

transthyretin amyloidosis

Bridgebio sets its heart on besting Pfizer

EP Vantage

Fri, 12/3/21 - 10:31 am

transthyretin amyloid cardiomyopathy